Oral Session 3-11B AML: FLT3 mutations

[OS3-11B-5] Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed/refractory AML

Kensuke Usuki¹, Hiroshi Handa², Ilseung Choi³, Takahiro Yamauchi⁴, Hiroatsu Iida⁵, Tomoko Hata⁶, Shoichi Ohwada⁷, Noriko Okudaira⁷, Kota Nakamura⁷, Sakura Sakajiri⁸ (1.NTT Medical Center Tokyo, Tokyo, Japan, 2.Gunma University Hospital, Maebashi, Japan, 3.National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 4.University of Fukui Hospital, Fukui, Japan, 5.National Hospital Organization Nagoya Medical Center, Aichi, Japan, 6.Nagasaki University Hospital, Nagasaki, Japan, 7.Daiichi Sankyo Co., Ltd., Tokyo, Japan, 8.Juntendo University Urayasu Hospital, Urayasu, Japan)